- Home
- AXIL vs SCYX Comparison
AXIL vs SCYX Comparison
Compare AXIL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- SCYX
- Stock Information
- Founded
- AXIL 2015
- SCYX 1999
- Country
- AXIL United States
- SCYX United States
- Employees
- AXIL N/A
- SCYX N/A
- Industry
- AXIL Package Goods/Cosmetics
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- AXIL Consumer Discretionary
- SCYX Health Care
- Exchange
- AXIL Nasdaq
- SCYX Nasdaq
- Market Cap
- AXIL 36.5M
- SCYX 28.5M
- IPO Year
- AXIL N/A
- SCYX 2014
- Fundamental
- Price
- AXIL $5.07
- SCYX $0.70
- Analyst Decision
- AXIL
- SCYX
- Analyst Count
- AXIL 0
- SCYX 0
- Target Price
- AXIL N/A
- SCYX N/A
- AVG Volume (30 Days)
- AXIL 13.5K
- SCYX 127.6K
- Earning Date
- AXIL 08-14-2025
- SCYX 08-07-2025
- Dividend Yield
- AXIL N/A
- SCYX N/A
- EPS Growth
- AXIL 93.65
- SCYX N/A
- EPS
- AXIL 0.29
- SCYX N/A
- Revenue
- AXIL $27,007,463.00
- SCYX $2,630,000.00
- Revenue This Year
- AXIL N/A
- SCYX $463.61
- Revenue Next Year
- AXIL N/A
- SCYX $310.80
- P/E Ratio
- AXIL $17.62
- SCYX N/A
- Revenue Growth
- AXIL N/A
- SCYX N/A
- 52 Week Low
- AXIL $3.54
- SCYX $0.66
- 52 Week High
- AXIL $10.75
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- AXIL 41.24
- SCYX 40.46
- Support Level
- AXIL $4.84
- SCYX $0.70
- Resistance Level
- AXIL $5.30
- SCYX $0.75
- Average True Range (ATR)
- AXIL 0.46
- SCYX 0.04
- MACD
- AXIL -0.02
- SCYX 0.00
- Stochastic Oscillator
- AXIL 17.61
- SCYX 32.29
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.